Skip to main content
. 2017 Jun 27;8(49):84996–85013. doi: 10.18632/oncotarget.18662

Figure 3. ROC curves were used to determine the cutoff score for the expression of Ki67 in breast cancer patients.

Figure 3

The sensitivity and specificity for tumor size (A), clinical stage (B), lymph node metastasis (C), HER2 status (D), RFS (E), and OS (F) were plotted for the expression of Ano1. The areas under curves (AUC) and P values were indicated.